Correction: The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy

Correction: The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy

Bibliographic Details
Main Authors:	Yan-jiao Cheng, Miao Wang, Jia Wang, Zhao Cui, Ming-hui Zhao
Format:	Article
Language:	English
Published:	BMC 2023-04-01
Series:	European Journal of Medical Research
Online Access:	https://doi.org/10.1186/s40001-023-01110-w

Similar Items

The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy
by: Yan-jiao Cheng, et al.
Published: (2023-03-01)

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy
by: Karine Dahan, et al.
Published: (2018-03-01)

The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy
by: Yang Chen, et al.
Published: (2023-12-01)

Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies
by: Xue Li, et al.
Published: (2024-12-01)

Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.
by: Kei Hihara, et al.
Published: (2016-01-01)

PLA2R antibody, PLA2R rs4664308 polymorphism and PLA2R mRNA levels in Tunisian patients with primary membranous nephritis
by: Tarak Dhaouadi, et al.
Published: (2020-01-01)

Temporal association between PLA2R antibodies and clinical outcomes in primary membranous nephropathy
by: Ramachandran, R, et al.
Published: (2017)

Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy
by: Ying Zhang, et al.
Published: (2023-12-01)

Favorable outcome in PLA2R positive HBV-associated membranous nephropathy
by: Ruiying Chen, et al.
Published: (2022-07-01)

Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels
by: Yuemeng Sun, et al.
Published: (2022-12-01)

The value of PLA2R antigen and IgG subclass staining relative to anti-PLA2R seropositivity in the differential diagnosis of membranous nephropathy
by: Dóra Bajcsi, et al.
Published: (2023-08-01)

PLA2R-positive membranous nephropathy in IgG4-related disease
by: Yusuke Ushio, et al.
Published: (2024-02-01)

The Intensity of PLA2R and C4d Immunoexpression in Primary Membranous Nephropathy
by: Deniz Filinte, et al.
Published: (2020-06-01)

Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role
by: Wenbin Liu, et al.
Published: (2019-08-01)

Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection
by: Xiaodan Li, et al.
Published: (2024-09-01)

PLA2R related primary membranous nephropathy in a hepatitis C positive patient
by: Ramachandran, R, et al.
Published: (2018)

A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy
by: Pingna Zhang, et al.
Published: (2021-01-01)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
by: Cheng Xue, et al.
Published: (2023-09-01)

Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy
by: Xiran Zhang, et al.
Published: (2025-02-01)

The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China
by: Hongxia Guo, et al.
Published: (2023-12-01)

Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach
by: Song Wang, et al.
Published: (2023-05-01)

Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?
by: Omar Ragy, et al.
Published: (2023-01-01)

Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?
by: Omar Ragy, et al.
Published: (2023-01-01)

Rheumatoid arthritis and PLA2R‐associated mebranous nephropathy. Cause or coincidence?
by: Lara Perea‐Ortega, et al.
Published: (2024-12-01)

Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
by: Kezhi Zhou, et al.
Published: (2024-01-01)

Phospholipase A2 receptor (PLA2R) related membranous nephropathy - not specific for idiopathic cases any more
by: Bahar Bastani
Published: (2018-01-01)

PM2.5-induced oxidative stress upregulates PLA2R expression in the lung and is involved in the pathogenesis of membranous nephropathy through extracellular vesicles
by: Wang Zhang, et al.
Published: (2024-12-01)

Clear cell renal cell carcinoma complicated with PLA2R-associated membranous nephropathy：three cases report and literature review
by: Sun Miao-xin, et al.
Published: (2025-02-01)

Pembrolizumab-Mediated Complete Remission of a PLA2R-Positive Paraneoplastic Membranous Nephropathy: A Case Report
by: Rayane Benyahia, et al.
Published: (2025-04-01)

Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm
by: Jinxu Huang, et al.
Published: (2025-12-01)

IgG4-related disease complicated by PLA2R-associated membranous nephropathy: A case report
by: Huang Meichun, et al.
Published: (2024-07-01)

Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy
by: Giuseppe Stefano Netti, et al.
Published: (2019-01-01)

The co-occurrence of sarcoidosis and anti-PLA2R-associated membranous nephropathy in a patient with underlying genetic susceptibility
by: Ying Ding, et al.
Published: (2024-06-01)

Lectin Complement Pathway Activation is Associated with Massive Proteinuria in PLA2R-Positive Membranous Nephropathy: A Retrospective Study
by: Li J, et al.
Published: (2023-05-01)

Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatment
by: Francisco José de la Prada Álvarez, et al.
Published: (2024-03-01)

Clinical Features and Pathology of PLA2R and THSD7A-Associated Membranous Nephropathy: A Single-Center Study from China
by: Pan Y, et al.
Published: (2024-07-01)

PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study
by: Yiqing Huang, et al.
Published: (2022-10-01)

Nephrotic syndrome, anti-PLA2R and membranous glomerulonephritis. Is the renal biopsy necessary?
by: Raúl Alvarado, et al.
Published: (2017-07-01)

First case report of PLA2R-related monotypic (IgG-κ positive) membranous nephropathy concurrent with leukocyte chemotactic factor 2 amyloidosis
by: Jing Xu, et al.
Published: (2023-09-01)

VEGFA promotes the occurrence of PLA2R-associated idiopathic membranous nephropathy by angiogenesis via the PI3K/AKT signalling pathway
by: Ben Ke, et al.
Published: (2022-09-01)